JP6764859B2 - 腫瘍崩壊性腫瘍ウイルスおよび使用の方法 - Google Patents

腫瘍崩壊性腫瘍ウイルスおよび使用の方法 Download PDF

Info

Publication number
JP6764859B2
JP6764859B2 JP2017515974A JP2017515974A JP6764859B2 JP 6764859 B2 JP6764859 B2 JP 6764859B2 JP 2017515974 A JP2017515974 A JP 2017515974A JP 2017515974 A JP2017515974 A JP 2017515974A JP 6764859 B2 JP6764859 B2 JP 6764859B2
Authority
JP
Japan
Prior art keywords
protein
modified
recombinant adenovirus
adenovirus
rapamycin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2017515974A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017534263A (ja
JP2017534263A5 (enExample
Inventor
クロダーグ オーシア，
クロダーグ オーシア，
シゲキ ミヤケ−ストナー，
シゲキ ミヤケ−ストナー，
Original Assignee
ソーク インスティテュート フォー バイオロジカル スタディーズ
ソーク インスティテュート フォー バイオロジカル スタディーズ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ソーク インスティテュート フォー バイオロジカル スタディーズ, ソーク インスティテュート フォー バイオロジカル スタディーズ filed Critical ソーク インスティテュート フォー バイオロジカル スタディーズ
Publication of JP2017534263A publication Critical patent/JP2017534263A/ja
Publication of JP2017534263A5 publication Critical patent/JP2017534263A5/ja
Priority to JP2020153724A priority Critical patent/JP7416423B2/ja
Application granted granted Critical
Publication of JP6764859B2 publication Critical patent/JP6764859B2/ja
Priority to JP2023216375A priority patent/JP2024038030A/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A61K35/761—Adenovirus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10332—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2810/00—Vectors comprising a targeting moiety
    • C12N2810/50—Vectors comprising as targeting moiety peptide derived from defined protein
    • C12N2810/60—Vectors comprising as targeting moiety peptide derived from defined protein from viruses
    • C12N2810/6009—Vectors comprising as targeting moiety peptide derived from defined protein from viruses dsDNA viruses
    • C12N2810/6018—Adenoviridae
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2810/00—Vectors comprising a targeting moiety
    • C12N2810/50—Vectors comprising as targeting moiety peptide derived from defined protein
    • C12N2810/80—Vectors comprising as targeting moiety peptide derived from defined protein from vertebrates
    • C12N2810/85—Vectors comprising as targeting moiety peptide derived from defined protein from vertebrates mammalian
    • C12N2810/855—Vectors comprising as targeting moiety peptide derived from defined protein from vertebrates mammalian from receptors; from cell surface antigens; from cell surface determinants

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2017515974A 2014-09-24 2015-09-23 腫瘍崩壊性腫瘍ウイルスおよび使用の方法 Active JP6764859B2 (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2020153724A JP7416423B2 (ja) 2014-09-24 2020-09-14 腫瘍崩壊性腫瘍ウイルスおよび使用の方法
JP2023216375A JP2024038030A (ja) 2014-09-24 2023-12-22 腫瘍崩壊性腫瘍ウイルスおよび使用の方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462054724P 2014-09-24 2014-09-24
US62/054,724 2014-09-24
PCT/US2015/051745 WO2016049201A1 (en) 2014-09-24 2015-09-23 Oncolytic tumor viruses and methods of use

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2020153724A Division JP7416423B2 (ja) 2014-09-24 2020-09-14 腫瘍崩壊性腫瘍ウイルスおよび使用の方法

Publications (3)

Publication Number Publication Date
JP2017534263A JP2017534263A (ja) 2017-11-24
JP2017534263A5 JP2017534263A5 (enExample) 2018-09-27
JP6764859B2 true JP6764859B2 (ja) 2020-10-07

Family

ID=55581955

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2017515974A Active JP6764859B2 (ja) 2014-09-24 2015-09-23 腫瘍崩壊性腫瘍ウイルスおよび使用の方法
JP2020153724A Active JP7416423B2 (ja) 2014-09-24 2020-09-14 腫瘍崩壊性腫瘍ウイルスおよび使用の方法
JP2023216375A Pending JP2024038030A (ja) 2014-09-24 2023-12-22 腫瘍崩壊性腫瘍ウイルスおよび使用の方法

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2020153724A Active JP7416423B2 (ja) 2014-09-24 2020-09-14 腫瘍崩壊性腫瘍ウイルスおよび使用の方法
JP2023216375A Pending JP2024038030A (ja) 2014-09-24 2023-12-22 腫瘍崩壊性腫瘍ウイルスおよび使用の方法

Country Status (11)

Country Link
US (1) US20170202893A1 (enExample)
EP (2) EP4043021A3 (enExample)
JP (3) JP6764859B2 (enExample)
KR (3) KR20250081944A (enExample)
CN (1) CN108064275A (enExample)
AU (3) AU2015320665B2 (enExample)
CA (1) CA2961748A1 (enExample)
DK (1) DK3198009T3 (enExample)
ES (1) ES2899913T3 (enExample)
PL (1) PL3198009T3 (enExample)
WO (1) WO2016049201A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2021007392A (ja) * 2014-09-24 2021-01-28 ソーク インスティテュート フォー バイオロジカル スタディーズ 腫瘍崩壊性腫瘍ウイルスおよび使用の方法

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2903582C (en) 2013-03-14 2021-06-08 Salk Institute For Biological Studies Oncolytic adenovirus compositions
ES2837400T3 (es) * 2015-10-05 2021-06-30 Salk Inst For Biological Studi Adenovirus sintético con tropismo para los tejidos dañados para su uso en la promoción de la reparación de heridas y regeneración tisular
JP7015551B2 (ja) 2016-02-23 2022-02-15 ソーク インスティテュート フォー バイオロジカル スタディーズ ウイルス動態への影響を最小限にするための治療用アデノウイルスにおける外因性遺伝子発現
WO2017147265A1 (en) 2016-02-23 2017-08-31 Salk Institute For Biological Studies High throughput assay for measuring adenovirus replication kinetics
CA3045892A1 (en) * 2016-12-12 2018-06-21 Salk Institute For Biological Studies Tumor-targeting synthetic adenoviruses and uses thereof
WO2018125970A1 (en) * 2016-12-30 2018-07-05 Salk Institute For Biological Studies Synthetic adenoviruses targeting bone tissue and uses thereof
SG11201906973TA (en) * 2017-01-30 2019-08-27 Epicentrx Inc Multiple transgene recombinant adenovirus
EA201990822A1 (ru) 2017-04-12 2020-01-09 Эписентарикс, Инк. Иммуномодулирующие слитые белки
EP3773649A4 (en) 2018-03-28 2022-02-23 EpicentRx, Inc. PERSONALIZED CANCER VACCINE
BR112020019942A2 (pt) * 2018-04-09 2021-01-26 Salk Institute For Biological Studies composições de adenovírus oncolítico com propriedades de replicação aprimoradas
CN111363726A (zh) * 2018-12-26 2020-07-03 上海元宋生物技术有限公司 表达干扰素的溶瘤病毒及其应用
WO2020172509A1 (en) * 2019-02-21 2020-08-27 Unleash Immuno Oncolytics, Inc. Oncolytic adenoviral vector and methods of use
US20220354911A1 (en) * 2019-09-05 2022-11-10 Klinikum Rechts Der Isar Der Technischen Universität München Treatment of tumors by a combination of an oncolytic adenovirus, a cdk4/6 inhibitor and a further therapeutically active agent
EP3812465A1 (en) * 2019-10-21 2021-04-28 Universität Ulm Adenovirus comprising a modified adenovirus hexon protein
JP2023513794A (ja) * 2020-02-14 2023-04-03 ソーク インスティテュート フォー バイオロジカル スタディーズ Ｕｌｋ１／２の阻害剤およびその使用方法
AU2021306714A1 (en) * 2020-07-06 2023-02-02 Salk Institute For Biological Studies Oncolytic adenovirus with replication selectivity based on status of p53 transcriptional activity
WO2022236080A2 (en) * 2021-05-06 2022-11-10 Asimov Inc. Compositions and methods for adeno-associated viral production

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030138405A1 (en) * 2001-04-17 2003-07-24 Juan Fueyo Conditionally replicative adenovirus to target the Rb and Rb-related pathways
ATE546531T1 (de) * 2003-12-31 2012-03-15 Kalobios Inc Transaktivierungssystem für säugerzellen
US7473418B2 (en) * 2004-03-25 2009-01-06 Cell Genesys, Inc. Pan cancer oncolytic vectors and methods of use thereof
EP2606127B1 (en) * 2010-08-16 2019-03-20 Salk Institute For Biological Studies Adenoviral assembly method
CA2867129C (en) * 2012-03-13 2023-11-21 Salk Institute For Biological Studies Selective cell targeting using adenovirus and chemical dimers
CA2903582C (en) * 2013-03-14 2021-06-08 Salk Institute For Biological Studies Oncolytic adenovirus compositions
WO2014170389A1 (en) * 2013-04-18 2014-10-23 Tilt Biotherapeutics Oy Enhanced adoptive cell therapy
DK3198009T3 (da) 2014-09-24 2021-11-22 Salk Inst For Biological Studi Onkolytiske tumorvira og anvendelsesfremgangsmåder

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2021007392A (ja) * 2014-09-24 2021-01-28 ソーク インスティテュート フォー バイオロジカル スタディーズ 腫瘍崩壊性腫瘍ウイルスおよび使用の方法
JP7416423B2 (ja) 2014-09-24 2024-01-17 ソーク インスティテュート フォー バイオロジカル スタディーズ 腫瘍崩壊性腫瘍ウイルスおよび使用の方法
JP2024038030A (ja) * 2014-09-24 2024-03-19 ソーク インスティテュート フォー バイオロジカル スタディーズ 腫瘍崩壊性腫瘍ウイルスおよび使用の方法

Also Published As

Publication number Publication date
AU2022203504B2 (en) 2025-02-20
JP2017534263A (ja) 2017-11-24
EP4043021A3 (en) 2022-11-23
AU2015320665B2 (en) 2022-06-16
KR20230165385A (ko) 2023-12-05
EP3198009A1 (en) 2017-08-02
AU2022203504A1 (en) 2022-06-09
JP7416423B2 (ja) 2024-01-17
EP3198009A4 (en) 2018-09-05
JP2024038030A (ja) 2024-03-19
KR102608590B1 (ko) 2023-12-01
EP4043021A2 (en) 2022-08-17
KR20250081944A (ko) 2025-06-05
AU2015320665A1 (en) 2017-04-06
EP3198009B1 (en) 2021-09-08
JP2021007392A (ja) 2021-01-28
ES2899913T3 (es) 2022-03-15
WO2016049201A1 (en) 2016-03-31
KR20170063801A (ko) 2017-06-08
KR102814615B1 (ko) 2025-05-28
PL3198009T3 (pl) 2022-01-24
AU2025203440A1 (en) 2025-06-05
CN108064275A (zh) 2018-05-22
DK3198009T3 (da) 2021-11-22
US20170202893A1 (en) 2017-07-20
CA2961748A1 (en) 2016-03-31

Similar Documents

Publication Publication Date Title
JP6764859B2 (ja) 腫瘍崩壊性腫瘍ウイルスおよび使用の方法
US20220339219A1 (en) Method for reversing multiple resistance in animal cells
JP5618896B2 (ja) 新規アデノウイルス、それをコードする核酸及びその使用
JP5873893B2 (ja) アデノウイルスおよびそれをコードしている核酸の新たな使用
US20120039877A1 (en) E1-minus adenoviruses and use thereof
Bieler et al. Novel three-pronged strategy to enhance cancer cell killing in glioblastoma cell lines: histone deacetylase inhibitor, chemotherapy, and oncolytic adenovirus dl520
JP2016516407A (ja) 腫瘍溶解性アデノウイルス組成物
JP2021517119A (ja) 腫瘍溶解性アデノウイルスとｃｄｋ４／６阻害剤との組み合わせによる腫瘍の処置
Chen et al. Advancing lung cancer treatment with combined c-met promoter-driven oncolytic adenovirus and rapamycin
AU2015201828B2 (en) Novel use of adenoviruses and nucleic acids coding therefor

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180814

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20180814

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20190822

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20191118

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200116

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20200716

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20200813

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20200914

R150 Certificate of patent or registration of utility model

Ref document number: 6764859

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250